The Ascension Via Christi Cancer Center in Wichita has been approved as a site for a new therapy for advanced metastatic prostate cancer.
The Center at 817 North Emporia is the first in Kansas to be approved for the long-awaited Pluvicto therapy. The FDA-approved therapy has been shown in studies to improve survival rates, slow the disease’s progression and improve the quality of life for patients.
Pluvicto is a targeted therapy that uses radioactive atoms to find and destroy cancer cells that produce a prostate-specific membrane antigen (PSMA), while sparing healthy tissue and cells. The location in the body of these cancer cells is identified with a positron emission tomography (PET) scan using a radio-tracer with a low amount of radiation. A second radioactive agent (Pluvicto) specifically targets and destroys the PSMA-positive cells.
Radiation oncologist David Bryant, MD, medical director for the Ascension Via Christi Cancer Center, said in a press release that this is part of a “designer” class of therapies that is specifically designed for and tailored to the needs of each individual patient.
